BackAutolus Therapeutics plc Overview

Autolus Therapeutics plc Total Assets

Track Autolus Therapeutics plc's total assets ($530M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$527.07M
29.38% YoYΔ $-219.27M vs prior year quarter

Peer average

Loading

Autolus Therapeutics plc Total Assets History

Loading

Autolus Therapeutics plc vs. peers: Total Assets Comparison

Loading

Autolus Therapeutics plc Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Autolus Therapeutics plc (AUTL) FAQ

Autolus Therapeutics plc's total assets stands at $530M as of March 2026. That compares with $750M in the prior-year period — down 29.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Autolus Therapeutics plc reported $530M in total assets versus $750M a year earlier — a 29.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $750M in the prior-year period — down 29.4% year over year. Sustained growth in total assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Autolus Therapeutics plc's total assets evolved across reporting periods, while the comparison chart places AUTL next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total assets is commonly used to spot outliers. Autolus Therapeutics plc's reading of $530M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.